{
    "nct_id": "NCT05372354",
    "official_title": "An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants With Relapsed or Refractory Multiple Myeloma",
    "inclusion_criteria": "* Relapsed or refractory multiple myeloma (MM) and must:\n\n  1. Have documented disease progression during or after their last myeloma therapy.\n  2. For Part 1 Dose Finding: Be refractory to, intolerant to, or not a candidate for available, established therapies known to provide clinical benefit in MM; For Part 2 Dose Expansion: Be refractory to or have relapsed after at least 2 prior lines of therapy that include an immunomodulatory drug (IMiD), a proteasome inhibitor, an anti-CD38 mAb, and a T-cell redirecting therapy (TRT, eg, a CAR-T or T-cell engaging bispecific treatment) unless the participant is not a candidate for TRT.\n* Must have measurable disease.\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.\n* Agree to follow the CC-92480 Pregnancy Prevention Plan (PPP).\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known active or history of central nervous system (CNS) involvement of MM\n* Plasma cell leukemia; Waldenstrom's macroglobulinemia; polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome; or clinically significant light-chain amyloidosis.\n* Impaired cardiac function or clinically significant cardiac disease\n* Previous SARS-CoV-2 infection within 14 days for asymptomatic or mild symptomatic infections or 28 days for severe/critical illness prior to Cycle 1 Day 1 (C1D1)\n* For Part 1: received prior therapy with CC-92480\n* For Part 2: received prior therapy with CC-92480, tazemetostat, BMS-986158, or trametinib\n* Previously received allogeneic stem-cell transplant at any time or received autologous stem-cell transplant within 12 weeks of initiating study treatment\n* Received any of the following within 14 days prior to initiating study treatment:\n\n  1. Plasmapheresis\n  2. Major surgery\n  3. Radiation therapy other than local therapy for myeloma associated bone lesions\n  4. Use of any systemic anti-myeloma drug therapy\n* Used any investigational agents within 28 days or 5 half-lives (whichever is shorter) prior to initiating study treatment\n* COVID-19 vaccine within 14 days prior to C1D1\n\nOther protocol-defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": ""
}